Roberts Capital Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Roberts Capital Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-485	Closed	-$216K	–	97
2025 Q2	$216K	Sell	485 -89	-16%	-$41K	0.16%	77
2025 Q1	$278K	Hold	574	–	–	0.24%	83
2024 Q4	$231K	Hold	574	–	–	0.19%	80
2024 Q3	$267K	Hold	574	–	–	0.23%	82
2024 Q2	$240K	Hold	574	–	–	0.23%	85
2024 Q1	$240K	Buy	+574	New	+$243K	0.23%	85
2022 Q3	$178K	Hold	616	–	–	0.26%	85
2022 Q2	$174K	Hold	616	–	–	0.24%	84
2022 Q1	$161K	Hold	616	–	–	0.17%	95
2021 Q4	$135K	Buy	+616	New	+$120K	0.13%	94

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Roberts Capital Advisors's VRTX Position: Q3 2025 in Review

Roberts Capital Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q3 2025, closing a stake of 485 shares — an estimated $216K sold.

Roberts Capital Advisors first reported a position in VRTX in Q4 2021 and held it in 10 quarters. The position peaked at $278K in Q1 2025. 1,519 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.

Roberts Capital Advisors reported no remaining Vertex Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Roberts Capital Advisors sold 485 Vertex Pharmaceuticals shares in Q3 2025, an estimated $216K.
Roberts Capital Advisors first reported a position in Vertex Pharmaceuticals in Q4 2021 and held it in 10 quarters.
Roberts Capital Advisors's Vertex Pharmaceuticals position peaked at $278K in Q1 2025.
1,519 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.

Based on Roberts Capital Advisors's 13F filing for Q3 2025, filed 13 Nov 2025.